CARDIOMAGNYL: EFFICACY AND SAFETY

Download full text PDF
Issue: 
11
Year: 
2015

T. Potupchik (1), Candidate of Medical Sciences; O. Veselova (1), Candidate of Medical Sciences; L. Evert (2,3), MD; E. Okladnikova (1), Candidate of Medical Sciences; M. Anisimova (1); I. Bryukhanova (1) 1 -Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University 2 -Research Institute for Medical Problems of the North, Krasnoyarsk 3 -Medical and Psychosocial Institute, N.F. Katanov Khakass State University, Ministry of Education and Science, Abakan

The paper considers the efficiency and safety of using a buffered acetylsalicylic acid (ASA) formulation in therapeutic practice. It shows its advantage over other ASA formulations.
Keywords: 
acetylsalicylic acid
Cardiomagnyl
platelets
thromboxane A2
cardiovascular diseases

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Barkagan Z.S., Kotovschikova E.F. Sravnitel'nyj analiz osnovnyh i pobochnyh effektov razlichnyh form atsetilsalitsilovoj kisloty // Klin. farmakol. i ter. – 2004; 13 (3): 1–4.
  2. Vertkin A.L., Aristarhova O.Ju., Adonina E.V. i dr. Bezopasnost' i farmakoekonomicheskaja effektivnost' primenenija razlichnyh preparatov atsetilsalitsilovoj kisloty u patsientov s IBS. RMZh // Kardiologija. – 2009; 17 (9): 570–5.
  3. Giljarov M.Ju. Mesto atsetilsalitsilovoj kisloty v terapii aterotromboza i ego oslozhnenij // Farmateka. – 2011; 15: 40–3.
  4. Zhitnikova L.M. Atsetilsalitsilovaja kislota v profilaktike i lechenii serdechno-sosudistyh zabolevanij: klinicheskie rekomendatsii dlja praktikujuschih vrachej // RMZh. – 2012; 14: 708–13.
  5. Nasonov E.L., Karateev A.E. Porazhenija zheludka, svjazannye s priemom nesteroidnyh protivovospalitel'nyh preparatov // Klin. meditsina. – 2000; 78 (3): 4–10.
  6. Fonjakin A.V., Geraskina L.A. Kardionevrologicheskie aspekty antitrombotsitarnoj terapii vo vtorichnoj profilaktike serdechno-sosudistyh zabolevanij // Kardiologija. – 2011; 9: 75–81.
  7. Potupchik T.V., Veselova O.F., Evert L.S. Geviskon pri gastroezofageal'noj refljuksnoj bolezni // Vrach. – 2015; 5: 26–30.
  8. Savchenko E.A., Grinshtejn Ju.I., Savchenko A.A. i dr. Zavisit li aspirinorezistentnost' ot formy aspirina i metabolicheskoj aktivnosti trombotsitov u bol'nyh s ishemicheskoj bolezn'ju serdtsa posle aortokoronarnogo shuntirovanija // Sibirskoe med. obozrenie.– 2008; 4: 32–7.
  9. Sychev D.A. Atsetilsalitsilovaja kislota // Spravochnik poliklinicheskogo vracha. – 2015; 1: 51–3.
  10. Jakovenko E.P., Krasnolobova L.P., Jakovenko A.V. i dr. Vlijanie preparatov atsetilsalitsilovoj kisloty na morfofunktsional'noe sostojanie slizistoj obolochki zheludka u kardiologicheskih patsientov pozhilogo vozrasta // Serdtse. – 2013; 12 (3): 145–50.
  11. Brooks P., Day R. Nonsteroidalantiinflammatory drugs – differences and similarities // N. Engl. J. Med. – 1991; 324 (24): 1716–25.
  12. Chen Z. CAST: randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke // Lancet. – 1997; 349: 1641–9.
  13. Endo H., Sakaib E., Higurashib T. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy // Dig. Liver Dis. – 2012; 44: 833–8.
  14. Gasbarrini G., Andreone P., Baraldini M. et al. Antacids in gastric ulcer treatment: evidence of cytoprotection // Scand. J. Gastroenterol. – 1990; 25 (Suppl. 174): 44–7.
  15. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. Published online: December 17, 2012.
  16. Hamm C., Bassand J., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation // Eur. Heart. J. – 2011. Epub. a head of print.
  17. Hirata Y., Kataoka H., Shimura T. et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin // Scand. J. Gastroenterol. – 2011; 46: 803–9.
  18. Mancia G., Fagard R., Narkiewicz K. et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. – 2013; 31 (7): 1281–357.
  19. Patrono C., Coller B., Dalen J. et al. Platelet-active drugs: the relationship among dose, effectiveness, and side effects // Chest. – 2001; 199: 39–63.
  20. Sandercock P., Counsell C., Gubitz G. et al. Antiplatelet therapy for acute ischaemic stroke // Cochrane Database Syst. Rev. – 2008; 16: CD000029.
  21. The International Stroke Trial Collaborative Group The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke // Lancet. – 1997; 349: 1569–81.
  22. The ISIS-2 Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 // Lancet. – 1988; 2: 349–60.
  23. Van de Werf F., Bax J., Betriu A. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with persistent ST-segment elevation // Eur. Heart J. – 2008; 29: 2909–45.
  24. Wallace J., McKnight G. The mucoid cap over superficial gastric damage in the rat.A high-pH microenvironment dissipated by nonsteroidalantiinflammatory drugs and endothelin // Gastroenterology. – 1990; 99 (2): 295–304.
  25. Wijns W., Olh P., Anchin N. et al. ESC Guidelines on myocardial revascularization // Eur. Heart J. – 2010; 31: 2501–55.